Viatris Inc Ord Shs Stock Price, News & Analysis

Viatris' 2023 Sustainability Report focuses on initiatives to empower healthcare workers globally, addressing the critical shortfall projected by WHO of 10 million healthcare workers by 2030. The report highlights the NCD Academy, which offers free, web-based educational tools covering major non-communicable diseases (NCDs) and expanded in 2023 with courses on social determinants of health and chronic respiratory diseases.

In 2023, nearly 5,000 new users joined NCD Academy, impacting an estimated 12.6 million patients annually. Viatris also launched Viatris Connect Medical in several countries to keep healthcare professionals updated on the latest medical advances. Additionally, the company supported multiple educational programs worldwide, promoting equitable access to care.

Viatris aims to impact 100 million patients by 2025 through HCP education. The report underscores the importance of partnerships and digital solutions in overcoming barriers to equitable healthcare access.

Viatris, a global pharmaceutical company, emphasizes the importance of a flexible and diverse supply chain in its 2023 Sustainability Report. The company maintains a 90% global customer service level despite market volatility and supply chain disruptions. Viatris has Supply Chain colleagues in over 55 countries, monitoring demand and supply daily with a 24-month outlook.

The company has invested in facilities worldwide, including in lower- and middle-income countries (LMICs), to strengthen its global network and support local economic development. Notable projects include technology transfer in Vietnam and a WHO-accredited packaging facility in Zambia.

Viatris is progressing towards its goal of providing ARV therapy to 30 million HIV/AIDS patients by 2025. In 2023, they treated approximately 8.6 million patients, including 670,000 children. Since 2022, they've provided treatments for nearly 17 million adults and children living with HIV/AIDS.

Viatris, a global healthcare company, released its 2023 Sustainability Report, highlighting its strategy for sustainable access to medicine. The company's hybrid approach combines generics and brands to address global healthcare needs. Viatris' business model focuses on building and sustaining access to medicine at scale, serving patients and health systems worldwide.

Key points from the report include:

• In 2023, Viatris sold over 80 billion doses of medicine across 165+ countries
• The company offers treatments in 10+ major therapeutic areas
• Viatris is expanding into complex generics and novel products
• The company launched Breyna™, the first FDA-approved generic version of Symbicort®
• Viatris acquired development programs for Selatogrel and Cenerimod in 2024

The report emphasizes Viatris' commitment to access, partnerships, and sustainable operations to meet evolving healthcare needs globally.

On July 3, 2024, Viatris (NASDAQ: VTRS) announced the completion of its Over-the-Counter (OTC) business divestiture to Cooper Consumer Health, marking the substantial conclusion of all planned divestitures. This strategic move aims to simplify the company structure, enhance focus on growth areas, and increase shareholder value. Key transactions include the divestiture of its OTC business, Women's Healthcare business, and Active Pharmaceutical Ingredients (API) business in India. The proceeds will be used to achieve long-term financial goals, support shareholder returns, and invest in innovative assets. CEO Scott A. Smith emphasized the importance of this milestone in reinforcing Viatris' growth trajectory and expanding its product pipeline.

Viatris (NASDAQ: VTRS) announced that the U.S. Department of Justice (DOJ) no longer considers Mylan, a Viatris subsidiary, and its former President, Rajiv Malik, subjects of an antitrust investigation in the generic drug industry. Additionally, the DOJ's Civil Division will not take further action regarding a civil investigative demand on generic drug pricing and sales. Viatris has consistently maintained that Mylan found no evidence of wrongdoing. The company is now focused on defending itself against remaining civil lawsuits related to these matters. More details are available in Viatris' Quarterly Report on Form 10-Q for the quarter ended March 31, 2024.

Viatris (NASDAQ: VTRS), a global healthcare company, has been named to TIME's inaugural World's Most Sustainable Companies 2024 list. This recognition, presented by TIME and Statista, highlights companies excelling in corporate social responsibility across 30 countries. Viatris was assessed on over 20 sustainability indicators, including greenhouse gas emissions and compliance with international standards. Out of 5,000 companies evaluated, the top 500 were selected.

Lina Andersson, Viatris' Head of Global Sustainability, attributed the accolade to the company's commitment to sustainable operations and reliable global medicine supply. Viatris is a U.N. Global Compact signatory and aims to build sustainable access to medicine. The company has also been recognized on various other prestigious lists, including USA TODAY's America's Climate Leaders and Forbes' World's Best Employers. More details can be found in Viatris' 2023 Sustainability Report.

Viatris (NASDAQ: VTRS), a global healthcare company, has been named to TIME's World's Most Sustainable Companies 2024 list. This recognition, presented by TIME and Statista, acknowledges Viatris' commitment to sustainable practices and corporate social responsibility. Evaluated on over 20 key performance indicators, including greenhouse gas emissions and compliance with international reporting standards, Viatris stands among the top 500 companies from over 30 countries. This accolade reflects Viatris' efforts to maintain a reliable global supply of medicines and its role as a signatory to the U.N. Global Compact. Other recognitions in 2023 and 2024 include listings on USA TODAY's America's Climate Leaders, 3BL's 100 Best Corporate Citizens, and Forbes' World's Best Employers.

Viatris (NASDAQ: VTRS) is set to announce its Q2 2024 financial results on August 8, 2024, before the U.S. market opens. CEO Scott A. Smith and other executives will hold a webcast at 8:30 a.m. ET the same day to discuss the results. The webcast will be accessible live on Viatris' investor relations website, with a replay available afterward. Investors and the public can also join via phone at 844.308.3344 or 412.317.1896 for international callers.

Viatris (NASDAQ: VTRS), a global healthcare company, announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, in Miami Beach, Florida. CEO Scott A Smith and other executives will represent the company in a scheduled fireside chat at 9:20 a.m. ET.

Interested parties can access a live webcast of the event at the company’s investor relations website, with an archived version available post-event for a time.